Discover the Potential of {4-[(5,6-Diphenyl-2-pyrazinyl)(isopropyl)amino]butoxy}acetic Acid

A critical component in advanced pharmaceutical research and a key player in treating complex conditions.

Get a Quote & Sample

Key Advantages

Enhanced Therapeutic Efficacy

As a potent and selective IP receptor agonist, it offers improved therapeutic outcomes compared to other agonists, directly contributing to better patient care in conditions requiring prostacyclin pathway activation.

Extended Drug Action

The compound's ability to maintain near peak plasma levels for extended periods makes it an ideal candidate for developing long-acting pharmaceutical treatments, reducing the frequency of administration.

Facilitates Targeted Research

Its identification as a selexipag impurity and active metabolite makes it essential for researchers studying drug efficacy, metabolism, and developing new formulations for pulmonary arterial hypertension.

Key Applications

Pulmonary Arterial Hypertension

Crucial for developing advanced treatments for PAH, leveraging its IP receptor agonism for vasodilation and anti-platelet aggregation effects.

Pharmaceutical Research

Serves as a vital tool for studying drug mechanisms, metabolism, and developing novel therapeutic agents in cardiovascular and respiratory diseases.

Chemical Synthesis

A key building block and intermediate in the synthesis of complex organic molecules and potential drug candidates, supporting the fine chemical industry.

Impurity Profiling

Essential for quality control and analytical standards in the pharmaceutical industry, specifically in relation to Selexipag and its metabolites.